Is NVE Corporation (NASDAQ:NVEC) a buy in 2026?
Hold. NVE Corporation is a wait-and-watch at today's price, not a fresh buy.
A spintronics gem with bond-like dividends and software-like margins, but the growth story keeps stalling at the same revenue ceiling.
Where NVEC is headed
Picture NVE in mid-2028. Same Eden Prairie facility, same roughly 30 employees, same 78% gross margins, same $1 quarterly dividend going out to shareholders like clockwork. Revenue probably sits somewhere between $28M and $36M, depending on whether the medical device design wins from 2024-2025 actually ramp into production volume. This is not a company that transforms. It compounds slowly, throws off cash, and gets revalued only when the market remembers it exists.
Read the full Compass Direction on NVEC
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $100.95).
See the full NVEC analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is NVE Corporation (NASDAQ:NVEC) a buy in 2026?
Hold. NVE Corporation is a wait-and-watch at today's price, not a fresh buy. A spintronics gem with bond-like dividends and software-like margins, but the growth story keeps stalling at the same revenue ceiling.
What is NVEC's Compass Score?
NVE Corporation scores 82/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for NVEC?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the NVEC page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.